Following the launch of its urine-based Qsant assay later this year, the firm plans to develop updated versions of it with new biomarkers for different disease indications.
The startup will use the funds to support R&D and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.
The products combine next-generation sequencing and analysis with the company's NGSengine software to provide high-resolution HLA genotyping information.
The test, which was developed by researchers at the Cleveland Clinic and the University of Alabama, looks for RNA molecules in urine that indicate rejection.
The Swedish firm expects to soon receive a CE mark for its Chimerism NGS kit, which identifies hematopoietic stem cell transplant rejection using cellular material.
